NNG-DEPO vs RD01 (PEG-EPO)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline

NNG-DEPO · Stimus

Developed by Nanogen Pharmaceutical Biotechnology

Phase 3 in Chronic Kidney Diseasebiologic (registry-typed, subtype undisclosed)
Partial signal

NCT05585645 · Phase 3 · completed

The trial was randomized, double-blind, and actively controlled with Aranesp, enrolling 214 participants. However, its primary endpoint was a hemoglobin change measure rather than a hard clinical outcome, and no primary comparison results are available.

No aligned efficacy figure on record for this race.

RD01 (PEG-EPO)

Developed by Shenzhen Sciprogen Bio-pharmaceutical

Phase 2 in Chronic Kidney Diseasebiologic
Partial signal

NCT04231292 · Phase 2 · status unknown

This is a randomized, controlled trial (active and placebo comparator arms) using hemoglobin concentration, the disease-defining measure for anemia, as its primary endpoint, but only participants were masked (not investigators or assessors), and no results have yet been posted.

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNNG-DEPORD01 (PEG-EPO)
Kidney composite outcome—Not posted · NCT05585645—Not reported
UACR, % change—Not posted · NCT05585645—Not reported
eGFR slope—Not posted · NCT05585645—Not reported
Haemoglobin, change—Not posted · NCT05585645—Not reported

Kidney composite outcome

NNG-DEPO
—Not posted · NCT05585645
RD01 (PEG-EPO)
—Not reported

UACR, % change

NNG-DEPO
—Not posted · NCT05585645
RD01 (PEG-EPO)
—Not reported

eGFR slope

NNG-DEPO
—Not posted · NCT05585645
RD01 (PEG-EPO)
—Not reported

Haemoglobin, change

NNG-DEPO
—Not posted · NCT05585645
RD01 (PEG-EPO)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NNG-DEPO: no structured comparison results are available for Chronic Kidney Disease.

RD01 (PEG-EPO): no structured comparison results are available for Chronic Kidney Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNG-DEPO's landscape · RD01 (PEG-EPO)'s landscape